Acipimox-d4
Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1].
Product Specifications
CAS Number
1246816-28-3
Product Name Alternative
K-9321-d4
UNSPSC
12352005
Target
Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others
Field of Research
Metabolic Disease
Solubility
10 mM in DMSO
Smiles
[2H]C(C1=CN=C(C(O)=O)C([2H])=[N+]1[O-])([2H])[2H]
Molecular Formula
C6H2D4N2O3
Molecular Weight
158.15
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Esben Thyssen Vestergaard, et al. Short‐term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec; 83 (12) : 2671-2677.|[3]Y-L Wang-Fisher, et al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174 (2) :267-72.|[4]B Ahrén. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171 (2) :161-7.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
